Skip to main content

Advertisement

SpringerLink
Log in

Second–line chemotherapy for non—small–cell lung cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Most of the experience with second-line chemotherapy for non-small-cell lung cancer (NSCLC) comes from small phase II trials, which have shown disappointing or inconsistent results. The notable exception has been docetaxel, which has been extensively studied as a second-line therapy for NSCLC. On the basis of consistent phase II activity, two large randomized phase III trials were conducted for patients with advanced NSCLC that had progressed either on or after first-line platinum-based therapy. In one trial, docetaxel, at either 100 or 75 mg/m2, was compared with a regimen of either vinorelbine or ifosfamide. In the second trial, docetaxel 75 to 100 mg/m2 was compared with best supportive care. Both trials showed significant improvement in survival, time to progression, and quality of life in the patients receiving docetaxel versus the control therapy. Based on these two large trials, it appears that the use of second-line therapy with single-agent docetaxel at a dose of 75 mg/m2 every 3 weeks is a reasonable practice in patients who maintain a good performance status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995, 311:899–909.

    Google Scholar 

  2. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993, 11:1866–1872.

    PubMed  CAS  Google Scholar 

  3. Jaakkimainen L Goodwin PJ, Pater J, et al.: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall cell lung cancer. J Clin Oncol 1990, 8:1301–1309.

    PubMed  CAS  Google Scholar 

  4. RuckdeschelJC: Is chemotherapy for metastatic nonsmall cell lung cancer "worth it" [editorial]? J Clin Oncol 1990, 8:1293–1296.

    PubMed  CAS  Google Scholar 

  5. Rapp E, Pater JL, Willan A, et al.: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988, 6:633–641.

    PubMed  CAS  Google Scholar 

  6. Fossella FV, Lee JS, Shin DM, et al.: Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 1995, 1:645–651.

    Google Scholar 

  7. Burris H, Eckardt J, Fields S, et al.: Phase II trials of Taxotere with non-small cell lung cancer [abstract]. Proc ASCO 1993, 12:335A.

    Google Scholar 

  8. Gandara DR, Vokes E, Green M, et al.: Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer: a confirmation of prolonged survival in a multicenter trial [abstract]. Proc ASCO 1997, 16:454A.

    Google Scholar 

  9. Robinet G, Kleisbauer JP, Thomas P, et al.: Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC [abstract]. Proc ASCO 1997, 16:480A.

    Google Scholar 

  10. Fossella FV, DeVore R, Kerr R, et al.: Phase III trial of docetaxel 100 mg/m2 or 75 mg/m2 versus vinorelbine/ifosfamide for non-small cell lung cancer previously treated with platinum-based chemotherapy [abstract]. Proc ASCO 1999, 18:460A. Abstract from the first of two large randomized trials that demonstrate the clinical benefit of docetaxel for NSCLC in the second-line setting.

    Google Scholar 

  11. Shepherd F, Ramlau R, Mattson K, et al.: Randomized study of Taxotere versus best supportive care in non-small cell lung cancer patients previously treated with platinum-based chemotherapy [abstract]. Proc ASCO 1999, 18:463A. Abstract from the second of two large randomized trials demonstrating the clinical benefit of docetaxel for NSCLC in the second-line setting.

    Google Scholar 

  12. Fossella FV, Lee JS, Kau SW, et al.: Docetaxel for platinum-refractory non-small cell lung cancer: comparison of phase II results to historical controls [abstract]. Proc ASCO 1997, 16:468A.

    Google Scholar 

  13. Miller VA, Fossella FV, DeVore R, et al.: Docetaxel benefits lung cancer symptoms and quality of life in a randomized phase III study of non-small cell lung cancer patients previously treated with platinum-based therapy [abstract]. Proc ASCO 1999, 18:460A. Details of quality-of-life analysis reported in Fossella et al. [10••].

    Google Scholar 

  14. Murphy WK, Winn RJ, Huber M, et al.: Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy [abstract]. Proc ASCO 1994, 13:363A.

    Google Scholar 

  15. Socinski MA, Steagall A, Gillenwater H: Second-line chemotherapy with 96-hour infusional paclitaxel in refractory nonsmall cell lung cancer: report of a phase II trial. Cancer Invest 1999, 17:181–188.

    Article  PubMed  CAS  Google Scholar 

  16. Roa V, Conner A, Mitchell RB: Carboplatin and paclitaxel for advanced non-small cell lung cancer in previously treated patients [abstract]. Proc ASCO 1996, 15:403A.

    Google Scholar 

  17. Stewart DJ, Tomiak E, Goss G, et al.: Paclitaxel plus low dose hydroxyurea as second line therapy in non-small cell lung cancer [abstract]. Proc ASCO 1995, 14:367A.

    Google Scholar 

  18. Tan V, Herrera C, Einzig AI, et al.: Taxol is active as a 3 hour or 24 hour infusion in non-small cell lung cancer [abstract]. Proc ASCO 1995, 14:366A.

    Google Scholar 

  19. Ruckdeschel J, Wagner H, Williams C, et al.: Second-line chemotherapy for resistant metastatic non-small cell lung cancer: the role of Taxol [abstract]. Proc ASCO 1994, 13:357A.

    Google Scholar 

  20. Hainsworth JD, Thompson DA, Greco FA: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995, 13:1609–1614.

    PubMed  CAS  Google Scholar 

  21. Pronzato P, Landucci M, Vaira F, et al.: Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients. Anticancer Res 1994, 14:1413–1416.

    PubMed  CAS  Google Scholar 

  22. Rinaldi M, Della Giulia M, Venturo I, et al.: Vinorelbine as single agent in the treatment of advanced non-small cell lung cancer [abstract]. Proc ASCO 1994, 13:360A.

    Google Scholar 

  23. Santoro A, Maiorino L, Santoro M: Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer [abstract].Lung Cancer 1994, 11(suppl 1):130.

    Article  Google Scholar 

  24. Crino L, Mosconi AM, Scagliotti F, et al.: Salvage therapy with Gemcitabine (GEM) in pretreated advanced non-small cell lung cancer (NSCLC) [abstract]. Proc ASCO 1997, 16:446A.

    Google Scholar 

  25. Rosvold E, Langer CJ, Schilder R, et al.: Salvage therapy with gemcitbine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel (C-P) [abstract]. Proc ASCO 1998, 17:467A.

    Google Scholar 

  26. Guerra JA, Lianes P, Paz-Ares L, et al.: Efficacy and toxicity profile of gemcitabine in previously treated patients with non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer 1997, 18(suppl):28.

    Article  Google Scholar 

  27. Garfield DH, Dakhil SR, Whittaker TL, Keller AM: Phase II randomized multicenter trial of two dose schedules of gemcitabine as second line therapy in patients with advanced non-small cell lung cancer [abstract]. Proc ASCO 1998, 17:484A.

    Google Scholar 

  28. Fukuoka M, Takada M, Yokoyama A, et al.: Phase II studies of Gemcitabine for non-small cell lung cancer in Japan. Sem in Oncol 1997, 2(suppl7):S7.42-S7.46.

    Google Scholar 

  29. CPT-11 Cooperative Study Group: A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 18:1013–1019, 199

  30. Nakai H, Fukuoka M, Furuse K, et al.: An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 1991, 18:607–612.

    CAS  Google Scholar 

  31. Niitani H, Fukuoka M, Nagao K: Clinical development of irinotecan (CPT-11) in lung cancers. Lung Cancer 1994, 11(suppl2):30–31.

    Google Scholar 

  32. Rowinsky EK, Grochow LB, Hendricks CB, et al.: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992, 10:647–656.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 80, 77030, Houston, TX, USA

    Frank V. Fossella MD

Authors
  1. Frank V. Fossella MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fossella, F.V. Second–line chemotherapy for non—small–cell lung cancer. Curr Oncol Rep 2, 96–101 (2000). https://doi.org/10.1007/s11912-000-0016-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-000-0016-x

Keywords

Search

Navigation